Monument Capital Management Takes Position in Novartis AG $NVS

Monument Capital Management purchased a new position in Novartis AG (NYSE:NVS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,778 shares of the company’s stock, valued at approximately $484,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GFG Capital LLC bought a new stake in Novartis in the second quarter worth $26,000. WPG Advisers LLC purchased a new position in shares of Novartis in the 1st quarter worth about $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Novartis in the 2nd quarter worth about $30,000. Barrett & Company Inc. bought a new position in Novartis in the 2nd quarter worth about $31,000. Finally, MCF Advisors LLC grew its position in Novartis by 66.0% during the 2nd quarter. MCF Advisors LLC now owns 264 shares of the company’s stock valued at $32,000 after purchasing an additional 105 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. raised shares of Novartis from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Cfra Research raised shares of Novartis to a “hold” rating in a research report on Wednesday, October 29th. Morgan Stanley restated an “overweight” rating on shares of Novartis in a report on Wednesday, December 3rd. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $118.00 price objective (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. Finally, Cfra set a $126.00 target price on Novartis and gave the stock a “hold” rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $119.75.

Novartis Stock Up 0.6%

NVS opened at $136.92 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.88 and a debt-to-equity ratio of 0.50. The firm has a 50 day moving average price of $129.94 and a 200-day moving average price of $124.98. Novartis AG has a twelve month low of $96.91 and a twelve month high of $137.40. The stock has a market capitalization of $289.23 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 1.92 and a beta of 0.52.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The company had revenue of $14.36 billion during the quarter, compared to analysts’ expectations of $13.70 billion. During the same quarter in the prior year, the business posted $2.06 EPS. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. Equities research analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.